|
|
| (11) | Number of the document | C 1425001 |
| (68) | Number of the document | 1425001 |
| (21) | Application number for Supplementary Protection Certificate | PA 2014 019 |
| (22) | Date of filing the application | 2014-04-11 |
| (41) | Date of publication of the application | 2014-05-26 |
| Date of publication of SPC | 2015-06-25 | |
| (24) | Date of coming into effect of SPC | 2022-09-12 |
| (71) |
GLAXO GROUP LIMITED,
980 Great West Road, Brentford, Middlesex TW8 9GS,
GB
|
| (73) |
Glaxo Group Limited ,
GSK Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY,
GB
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (93) | EU/1/13/886/001-006, 2013-11-13 |
| (94) | 2027-09-12 |
| (95) | Vilanterolum |
| Request filed | SPC extension granted until | Request refused | |
| 2024-04-30 | 2028-03-12 |
| Payment date | Validity (years) | Amount | |
| 2025-08-20 | 4 | 347.00 EUR |
| 2026-09-12 |
| SPC term extension granted |